News and Trends 18 Nov 2022 Novavax’ COVID-19 vaccine gets expanded authorization for booster in adults Novavax, Inc., a U.S-based biotechnology company announced today (November 18) that Health Canada has granted expanded authorization for Covid-19 vaccine Nuvaxovid. The vaccine NVX-CoV2373 for active immunization to prevent the disease caused by severe acute respiratory syndrome (SARS-CoV-2) as a homologous booster in adults aged 18 and older. “Canadians now have access to our […] November 18, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2022 AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) for patients previously treated HER-2 positive advanced gastric cancer. The drug is also used for gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca […] November 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2022 Poolbeg-led consortium awarded €2.3m to develop oral vaccine platform EncOVac, a consortium led by Poolbeg Pharma, has been awarded €2.3m ($2.4 million) in non-dilutive grant funding to progress its Oral Vaccine Platform under the Irish Government’s Disruptive Technologies Innovation Fund (DTIF). Taking place over three years, the collaboration between Poolbeg Pharma, University College Dublin, Trinity College Dublin and AnaBio Technologies will result in the […] November 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 Nuance Pharma’s RSV vaccine cleared for trial in China Nuance Pharma says China’s Center for Drug Evaluation (CDE) has approved its investigational new drug (IND) application supporting its pivotal phase III clinical trial of MVA-BN RSV vaccine against respiratory syncytial virus (RSV) in adults in China. MVA-BN RSV is being developed for the prevention of RSV in older adults. The vaccine incorporates five distinct RSV […] November 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 14 Nov 2022 ChromaTwist lands second round of funding for fluorescent dyes for flow cytometry market ChromaTwist Ltd, a University of Birmingham spinout, has secured £487,000 ($573,000) of equity investment to develop its new class of fluorescent dyes for the flow cytometry reagent market. Existing investors, Angel from angelgroups and the University of Birmingham brought in funds which will allow ChromaTwist to continue product development with industry partners and enable rapid […] November 14, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Sanofi and GSK Covid-19 booster vaccine approved by European Commission Sanofi and GSK’s Covid booster vaccine has been approved in Europe. After the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn Beta, the vaccine was approved by the European Commission, as a booster for the prevention of Covid-19 in adults 18 years of age and older. […] November 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Does covid vaccination boost cancer treatment? Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. It was feared that vaccination against Covid-19 could reduce the success of cancer treatment or cause severe side effects. However, a recent study by the universities of Bonn, Germany, and Shanxi, China, say this isn’t the case. According […] November 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022Beyond Biotech podcast 21: CanSinoBIO, HTID, Longevity Science Foundation This week, we have three interviews, and four guests. We chat with Pierre Corneille VP of the HTFC, which is responsible for HealthTech Innovation Days; Sergey Jakimov, co-founder and managing partner of LongeVC and the Longevity Science Foundation’s CEO Lisa Ireland; and Pierre Morgon, executive vice president of CanSinoBIO. We also have our weekly contribution […] November 4, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Senescent cells as vaccines against cancer? Cancer cells have a series of features that allow the immune system to identify and attack them. However, these same cells create an environment that blocks immune cells and protects the tumor. This means immune cells cannot reach the cancer cells to remove them. The scientific community has been working to increase the effectiveness of […] November 3, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by ACROBiosystems 3 Nov 2022 Impacting vaccine development: COVID-19 and its implications for the future of vaccines The development of COVID-19 vaccines was an unprecedented achievement at a time of urgent medical need. We explore the novel technology platforms that went into their development and consider their long-term impact on vaccine research. Ever since the first vaccine against smallpox in the late 1700s, vaccines have gained a reputation as a critical tool […] November 3, 2022 - 8 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 The Native Antigen Company expands range of Omicron antigens to include BA.5 variant The Native Antigen Company today (November 2) announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant. The company, part of LGC Clinical Diagnostics, is a supplier of reagents enabling research into vaccines and diagnostics for emerging endemic infectious diseases. The new range of RBD (receptor binding domain) antigens […] November 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 AELIX Therapeutics publishes positive data on its HIV vaccine Positive results from a clinical study into biotech company, AELIX’ Therapeutics’, HIV vaccine have been published in Nature Medicine journal. The announcement came today (November 2) from the Spanish-based company that specializes in developing immunotherapies for HIV infection. Christian Brander, co-founder and chief scientific officer at AELIX, said: “We are excited to have published the […] November 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email